<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1196">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04765254</url>
  </required_header>
  <id_info>
    <org_study_id>ITH00131</org_study_id>
    <nct_id>NCT04765254</nct_id>
  </id_info>
  <brief_title>COVID-19 Infection in Diabetic Patients</brief_title>
  <official_title>Clinical Features of Diabetic Patients With COVID-19 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It was observed during the last period of COVID-19 pandemic that diabetic patients had a&#xD;
      worse prognosis and more deteriorated clinical features than other patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic patients infected with SAR-COV-19 were reported to have worse prognosis and faster&#xD;
      deterioration in addition to higher rate for ICU admission when compared to other infected&#xD;
      patients. In this study authors aim to investigate the certain cause for their case&#xD;
      deterioration to be modified for better prognosis&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 20, 2021</start_date>
  <completion_date type="Anticipated">April 10, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 20, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Investigation of bad prognosis cause for covid-19 diabetic patients</measure>
    <time_frame>30 days</time_frame>
    <description>number of diabetic patients with deteriorated case and to find the best hypoglycemic drug used for diabetic patients with covid-19 infection</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Covid19</condition>
  <condition>Diabete Type 2</condition>
  <condition>Non Diabetic Patients</condition>
  <condition>Chest CT Scan</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <description>COVID-19 infected patients with no other comorbidities and they take the routine protocol from the Egyptian ministry of health</description>
  </arm_group>
  <arm_group>
    <arm_group_label>diabetic group</arm_group_label>
    <description>COVID-19 infected patients with diabetes comorbidity and they receive the routine protocol for covid treatment in addition to their hypoglycemic drugs</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention as it is an observational study</intervention_name>
    <description>both groups will be monitored for the disease progress or deterioration and mortality rate</description>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>diabetic group</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum samoles for routine CBC, D dimer and INR tests&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients infected with COVID-19 either diabetic or have no comorbidities, inpatients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients infected with COVID-19 male or female 30 years old or more inpatients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  have othe comorbidities other than type 2 diabetes mellitus pregnant women below 30&#xD;
             years old&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dalia Zaafar, PhD</last_name>
    <phone>+201117922833</phone>
    <email>dr.moda88@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amal Ahmed, PhD</last_name>
    <phone>+201224847367</phone>
    <email>amalahmedhcp@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cairo University teaching hospitals</name>
      <address>
        <city>Cairo</city>
        <state>Kasr Al Ainy</state>
        <zip>11311</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amal Ahmed, PhD</last_name>
      <phone>+201224847367</phone>
      <email>amalahmedhcp@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Dalia Zaafar, PhD</last_name>
      <phone>+201117922833</phone>
      <email>dr.moda88@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 18, 2021</study_first_submitted>
  <study_first_submitted_qc>February 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>February 19, 2021</last_update_submitted>
  <last_update_submitted_qc>February 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Dalia K. Zaafar</investigator_full_name>
    <investigator_title>lecturer of pharmacology</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>prognosis</keyword>
  <keyword>mortality rate</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

